The case for cooperation in managing and maintaining the end of poliomyelitis: Stockpile needs and coordinated OPV cessation

MedGenMed Medscape General Medicine

Volumn 10, Issue 8, 2008, Pages

  Thompson, Kimberly M ^a   Duintjer Tebbens, Radboud J ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ORAL POLIOMYELITIS VACCINE;

ARTICLE; DRUG BLOOD LEVEL; DRUG COST; EPIDEMIC; ERADICATION THERAPY; HUMAN; MASS IMMUNIZATION; MEDICAL DECISION MAKING; POLIOMYELITIS; RISK ASSESSMENT; RISK MANAGEMENT; GAME; INTERNATIONAL COOPERATION; METHODOLOGY; PREVALENCE; PROPORTIONAL HAZARDS MODEL; RISK FACTOR;

GAME THEORY; HUMANS; INTERNATIONAL COOPERATION; POLIOMYELITIS; POLIOVIRUS VACCINE, ORAL; PREVALENCE; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; RISK FACTORS;

EID: 50949133715     PISSN: 15310132     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Hinman A. Eradication of vaccine-preventable diseases. Annu Rev Public Health. 1999;20:211-229.
2. Aylward B, Hennessey KA, Zagaria N, Olive J-M, Cochi S. When is a disease eradicable? 100 years of lessons learned. Am J Public Health. 2000;90:1515-1520.
3. Geoffard P-Y, Philipson T. Disease eradication private versus public vaccination. Am Econ Rev. 1997;87:222-230.
4. Barrett S, Hoel M. Optimal disease eradication. Environ Dev Econ. 2007;12:1-26.
5. Barrett S. Global disease eradication. J Eur Econ Assoc. 2003;1:591-600.
6. Barrett S. Eradication versus control: the economics of global infectious disease policies. Bull WHO. 2004;82:683-688.
7. Thompson KM, Duintjer Tebbens RJ. Eradication versus control for poliomyelitis: an economic analysis. Lancet. 2007;369:1363-1371.
8. World Health Organization. The Case for Completing Polio Eradication. 2007. Available at: http://www.polioeradication.org/content/general/ TheCase_FINAL.pdf Accessed July 30, 2008.
9. Sangrujee NK, Duintjer Tebbens RJ, Caceres VM, Thompson KM. Policy decision options during the first five years following certification of polio eradication. MedGenMed. 2003;5(4). Available at: http://www.medscape.com/viewarticle/464841 Accessed July 30, 2008.
10. Duintjer Tebbens RJ, Sangrujee N, Thompson KM. The costs of future polio risk management policies. Risk Anal. 2006;26:1507-1531.
11. Duintjer Tebbens RJ, Pallansch MA, Kew OM, et al. Risks of paralytic disease due to wild or vaccine-derived poliovirus after eradication. Risk Anal. 2006;26:1471-1505.
12. Aylward RB, Sutter RW, Cochi SL, Thompson KM, Jafari H, Heymann D. Risk management in a polio-free world. Risk Anal. 2006;26:1441-1448.
13. Thompson KM, Duintjer Tebbens RJ, Pallansch MA. Evaluation of response scenarios to potential polio outbreaks using mathematical models. Risk Anal. 2006;26:1541-1556.
14. Duintjer Tebbens RJ, Pallansch MA, Kew OM, Caceres VM, Sutter RW, Thompson KM. A dynamic model of poliomyelitis outbreaks: learning from the past to help inform the future. Am J Epidemiol. 2005;162:358-372.
15. Thompson KM, Duintjer Tebbens RJ, Pallansch MA, et al. The risks, costs, and benefits of future global policies for managing polioviruses. Am J Public Health. 2008;98:1322-1330.
16. Duintjer Tebbens RJ, Pallansch MA, Kew OM, et al. Uncertainty and sensitivity analyses of a decision analytic model for post-eradication polio risk management. Risk Anal. 2008;28:855-876.
17. Kew OM, Wright PF, Agol VI, et al. Circulating vaccine-derived polioviruses: current state of knowledge. WHO Bull. 2004;82:16-23.
18. World Health Organization. Conclusions and recommendations of the Advisory Committee on Poliomyelitis Eradication, Geneva, 11-12 October 2005. Wkly Epidemiol Rec. 2005;80:410-416.
19. World Health Organization. Polio Eradication Initiative. Cessation of Routine Oral Polio Vaccine (OPV) Use After Global Polio Eradication. Framework for National Policy Makers in OPV-Using Countries. Geneva, Switzerland: World Health Organization; 2005. Report No WHO/POLJ05.02.
20. World Health Organization. WHO Global Action Plan for Laboratory Containment of Wild Polioviruses. 2nd edition. Geneva, Switzerland: World Health Organization; 2004. Report No WHO/V&B/03.11.
21. Dowdle W, Van der Avoort H, de Gourville E, et al. Containment of polioviruses after eradication and OPV cessation: characterizing risks to improve management. Risk Anal. 2006;26:1449-1469.
22. Fenner F, Henderson DA, Arita I, Jezek Z, Ladnyi ID. Smallpox and its eradication. Geneva, Switzerland: World Health Organization; 1988.
23. Fine PEM, Clarkson JA. Individual versus public priorities in the determination of optimal vaccination policies. Am J Epidemiol. 1986;124:1012-1020.
24. Feudtner C, Marcuse EK. Ethics and immunization policy: promoting dialogue to sustain consensus. Pediatrics. 2001;107:1158-1164.
25. Heal G, Kunreuther H. You can only die once: interdependent security in an uncertain world. In: Richardson HW, Gordon P, Moore JE, eds. The Economic Impacts of Terrorist Attacks. Northampton, Mass: Edward Elgar Publishers; 2006:35-56.
26. Bauch CT, Earn DJD. Vaccination and the theory of games. PNAS. 2004;101:13391-13394.
27. Global Alliance for Vaccines and Immunization. Investment case for the polio stockpile. June 20, 2005. Available at: http://www.vaccinealliance.org/resources/ 16brd_07._Polio_Stockpile_investment_case.pdf Accessed July 30, 2008.
28. UN Population Division. World population prospects population database: the 2006 revision population database. 2007. Available at: http://esa.un.org/unpp Accessed July 30, 2008.
29. Normile D. Rinderpest: driven to extinction. Science. 2008;319:1606-1609.
30. Cuba IPV Study Group. Randomized, placebo-controlled trial of inactivated poliovirus vaccine in Cuba. N Engl J Med. 2007;356:1536-1544.
31. Bart K, Foulds J, Patriarca P. Global eradication of poliomyelitis: benefit-cost analysis. Bull WHO. 1996;74:35-45.
32. Centers for Disease Control and Prevention. Resurgence of wild poliovirus type 1 transmission and consequences of importation -- 21 countries, 2002-2005. MMWR Morbid Mortal Wkly Rep. 2006;55:145-150.
33. Centers for Disease Control and Prevention. Laboratory surveillance for wild and vaccine-derived polioviruses, January 2004 to June 2005. MMWR Morbid Mortal Wkly Rep. 2005;54:958-961.
34. Centers for Disease Control and Prevention. Laboratory surveillance for wild and vaccine-derived polioviruses, January 2006 to June 2007. MMWR Morbid Mortal Wkly Rep. 2007;56:965-969.
35. Miller MA, Sutter RW, Strebel PM, Hadler SC. Cost-effectiveness of incorporating inactivated poliovirus vaccine into the routine childhood immunization schedule. JAMA. 1996;276:967-971.
36. Kimman TG, Boot H. The polio eradication effort has been a great success - let's finish it and replace it with something even better. Lancet Infect Dis. 2006;6:675-678.
37. Aylward RB, Acharya A, England S, Agocs M, Linkins J. Global health goals: lessons from the worldwide effort to eradicate poliomyelitis. Lancet. 2003;362:909-914.